279 related articles for article (PubMed ID: 26891946)
21. Effect of brivaracetam on the anger levels of epilepsy patients. A prospective open-labelled controlled study.
Toledo M; Abraira L; Mazuela G; Quintana M; Cazorla S; Santamarina E
Seizure; 2019 Jul; 69():198-203. PubMed ID: 31079028
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
Benbadis S; Klein P; Schiemann J; Diaz A; Elmoufti S; Whitesides J
Epilepsy Behav; 2018 Mar; 80():129-134. PubMed ID: 29414542
[TBL] [Abstract][Full Text] [Related]
23. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
[TBL] [Abstract][Full Text] [Related]
24. Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents.
Schubert-Bast S; Willems LM; Kurlemann G; Knake S; Müller-Schlüter K; Rosenow F; Strzelczyk A
Epilepsy Behav; 2018 Dec; 89():89-93. PubMed ID: 30390435
[TBL] [Abstract][Full Text] [Related]
25. Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial.
O'Brien TJ; Borghs S; He QJ; Schulz AL; Yates S; Biton V
Epilepsia; 2020 Apr; 61(4):636-646. PubMed ID: 32221987
[TBL] [Abstract][Full Text] [Related]
26. Brivaracetam for the treatment of epilepsy.
Klein P; Tyrlikova I; Brazdil M; Rektor I
Expert Opin Pharmacother; 2016; 17(2):283-95. PubMed ID: 26760311
[TBL] [Abstract][Full Text] [Related]
27. Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy.
Fonseca E; Guzmán L; Quintana M; Abraira L; Santamarina E; Salas-Puig X; Toledo M
Epilepsy Behav; 2020 Jan; 102():106657. PubMed ID: 31731108
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy.
Gillis RME; Wammes-van der Heijden EA; Schelhaas HJ; Tan IY; Festen DAM; Majoie MHJM
Acta Neurol Belg; 2021 Jun; 121(3):677-684. PubMed ID: 32157673
[TBL] [Abstract][Full Text] [Related]
29. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
[TBL] [Abstract][Full Text] [Related]
30. A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization.
Trinka E; Tsong W; Toupin S; Patten A; Wilson K; Isojarvi J; James D
Epilepsy Res; 2020 Oct; 166():106403. PubMed ID: 32673969
[TBL] [Abstract][Full Text] [Related]
31. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST).
Lattanzi S; Canafoglia L; Canevini MP; Casciato S; Chiesa V; Dainese F; De Maria G; Didato G; Falcicchio G; Fanella M; Ferlazzo E; Fisco G; Gangitano M; Giallonardo AT; Giorgi FS; La Neve A; Mecarelli O; Montalenti E; Piazza F; Pulitano P; Quarato PP; Ranzato F; Rosati E; Tassi L; Di Bonaventura C;
CNS Drugs; 2021 Dec; 35(12):1289-1301. PubMed ID: 34476770
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies.
Tian X; Yuan M; Zhou Q; Wang X
Expert Opin Pharmacother; 2015; 16(12):1755-67. PubMed ID: 26165169
[TBL] [Abstract][Full Text] [Related]
33. Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?
Swallow E; Fang A; Signorovitch J; Plumb J; Borghs S
CNS Drugs; 2017 Oct; 31(10):899-910. PubMed ID: 28856580
[TBL] [Abstract][Full Text] [Related]
34. Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.
Schoemaker R; Wade JR; Stockis A
J Clin Pharmacol; 2016 Dec; 56(12):1591-1602. PubMed ID: 27146213
[TBL] [Abstract][Full Text] [Related]
35. Exceptional response to brivaracetam in a patient with refractory idiopathic generalized epilepsy and absence seizures.
Grande-Martín A; Sopelana-Garay D; Pardal-Fernández JM; Sánchez-Honrubia RM; Sánchez-Larsen ÁA
Epileptic Disord; 2018 Feb; 20(1):60-64. PubMed ID: 29160210
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study.
Asadi-Pooya AA; Sperling MR; Chung S; Klein P; Diaz A; Elmoufti S; Schiemann J; Whitesides J
Epilepsy Res; 2017 Mar; 131():70-75. PubMed ID: 28279891
[TBL] [Abstract][Full Text] [Related]
37. Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation.
Adewusi J; Burness C; Ellawela S; Emsley H; Hughes R; Lawthom C; Maguire M; McLean B; Mohanraj R; Oto M; Singhal S; Reuber M
Epilepsy Behav; 2020 May; 106():106967. PubMed ID: 32179501
[TBL] [Abstract][Full Text] [Related]
38. The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.
Russo E; Citraro R; Mula M
Expert Opin Drug Discov; 2017 Nov; 12(11):1169-1178. PubMed ID: 28829199
[TBL] [Abstract][Full Text] [Related]
39. Brivaracetam (Briviact) for epilepsy.
Med Lett Drugs Ther; 2016 Jul; 58(1499):95-6. PubMed ID: 27403785
[No Abstract] [Full Text] [Related]
40. Adjunctive Brivaracetam in Indian Patients with Uncontrolled Focal Epilepsy: Results from a Pooled Analysis of Two Double-Blind, Randomized, Placebo-Controlled Trials.
Srinivasa R; Sinha S; Parthasarthy S; Kothari S; Baviskar R; Jayalakshmi S; Sharma B; Garg RK; Desai J; Yardi N; Salvadeeswaran MS; Ravat S; Das M; Gursahani R; Suresh S; Rasal A; Elmoufti S
Neurol India; 2020; 68(6):1400-1408. PubMed ID: 33342876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
